Lucas Shelton, MD

Assistant Professor
Division of General Internal Medicine
University of Kentucky

In person and via Zoom

Upon completion of this activity, participants will be able to:

• Explain why to use PREVENT
• Incorporate changes from the 2025 HTN Guidelines and the 2026 Lipid Guidelines
• Describe which LLT to use in various scenarios

Disclosure of Financial Interest Summary

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing,marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant tif the educational content an individual can control is related to the business lines or products of the ineligible company.

The planners, faculty, and others in control of educational content for this educational activity have relevant financial relationship(s) to disclose: none

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off- label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off label uses.

Disclosure of relationships is not intended to suggest or condone commercial bias in any presentations, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation